The 4 analysts offering 12-month price forecasts for Checkpoint Therapeutics Inc have a median target of 21.00, with a high estimate of 47.00 and a low estimate of 8.00. The median estimate represents a +642.05% increase from the last price of 2.83.
The current consensus among 4 polled investment analysts is to Buy stock in Checkpoint Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.96
Reporting Date Mar 14
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.